Business Context and Reporting Period
This Form 8-K was filed by Manhattan Pharmaceuticals, Inc. on December 16, 2005, reporting events occurring on December 13, 2005. The filing addresses corporate governance matters regarding the composition of the Company's Compensation Committee.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board committee appointments and does not contain financial performance data.
Material Changes
The Board of Directors appointed Dr. Michael Weiser to the Compensation Committee. While AMEX listing standards generally require compensation committees to consist solely of independent directors, the Board utilized an exception allowing one non-independent director to serve if the committee has at least three members and the appointment is in the best interests of the issuer. Dr. Weiser is not considered "independent" because he received compensation exceeding $60,000 per year for consulting services from 2002 through 2004. The other three committee members (Neil Herskowitz, Malcolm Hoenlein, and Richard Steinhart) are independent.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of market risks. Management commentary is limited to the rationale for Dr. Weiser's appointment, citing his valuable experience in the corporate governance of other biotechnology companies. The filing notes that a director appointed under this exception is limited to two years of service on the compensation committee.
Key Facts for Investor Verification
- Dr. Michael Weiser was appointed to the Compensation Committee despite not meeting AMEX independence standards due to prior consulting compensation.
- The appointment relies on an AMEX exception permitting one non-independent director on a committee of at least three members.
- The Board determined Dr. Weiser's specific experience in biotechnology governance justifies the exception.
- Dr. Weiser's service on the committee is statutorily limited to two years under the applicable exception.
- This filing contains no financial results or operational updates for the period.